Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIEW 2: Aflibercept in Neovascular AMD
NCT00637377Phase 3Completed
- Sponsor
- Bayer
- Start
- Apr 2008
- Primary completion
- Sep 2010
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial of aflibercept in neovascular age-related macular degeneration (NVAMD) (4 arms), sponsored by Bayer. Primary endpoint: Percentage of Participants Who Maintained Vision (loss < 15 letters) at 52 weeks. Started Apr 2008; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00637377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00637377.